{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T12:57:05Z","timestamp":1777899425877,"version":"3.51.4"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-04747-z","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T23:22:26Z","timestamp":1774308146000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of RefluxStop for gastroesophageal reflux disease: analysis from an Italian healthcare perspective"],"prefix":"10.1186","volume":"26","author":[{"given":"Sam","family":"Harper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muralikrishnan","family":"Kartha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Mealing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Bona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Vincenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adolfo","family":"Renzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Bonavina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"issue":"5","key":"4747_CR1","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.mayocp.2025.01.022","volume":"100","author":"HR Phillips","year":"2025","unstructured":"Phillips HR, Kamboj AK, Leggett CL. Diagnosis and Management of Gastroesophageal Reflux Disease: A Concise Review for Clinicians. Mayo Clin Proc. 2025;100(5):882\u20139.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"4747_CR2","doi-asserted-by":"publisher","first-page":"97918","DOI":"10.4292\/wjgpt.v16.i1.97918","volume":"16","author":"N Wickramasinghe","year":"2025","unstructured":"Wickramasinghe N, Devanarayana NM. Insight into global burden of gastroesophageal reflux disease: Understanding its reach and impact. World J Gastrointest Pharmacol Ther. 2025;16(1):97918.","journal-title":"World J Gastrointest Pharmacol Ther"},{"issue":"3","key":"4747_CR3","doi-asserted-by":"publisher","first-page":"e13758","DOI":"10.1111\/ijcp.13758","volume":"75","author":"F Bert","year":"2021","unstructured":"Bert F, et al. Prevalence of gastro-oesophageal reflux symptoms: An Italian cross-sectional survey focusing on knowledge and attitudes towards lifestyle and nutrition. Int J Clin Pract. 2021;75(3):e13758.","journal-title":"Int J Clin Pract"},{"issue":"10","key":"4747_CR4","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1136\/gut.2007.145177","volume":"57","author":"RM Zagari","year":"2008","unstructured":"Zagari RM, et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett\u2019s oesophagus in the general population: the Loiano-Monghidoro study. Gut. 2008;57(10):1354\u20139.","journal-title":"Gut"},{"issue":"6","key":"4747_CR5","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S2468-1253(19)30408-X","volume":"5","author":"GBD","year":"2020","unstructured":"GBD. 2017 Gastro-oesophageal Reflux Disease Collaborators. The global, regional, and national burden of gastro-oesophageal reflux disease in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(6):561\u201381.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"4747_CR6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12876-018-0832-9","volume":"18","author":"I Martinucci","year":"2018","unstructured":"Martinucci I, et al. Gastroesophageal reflux symptoms among Italian university students: epidemiology and dietary correlates using automatically recorded transactions. BMC Gastroenterol. 2018;18(1):116.","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"4747_CR7","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1185\/030079905X38231","volume":"21","author":"F Pacini","year":"2005","unstructured":"Pacini F, et al. Burden of illness in Italian patients with gastro-oesophageal reflux disease. Curr Med Res Opin. 2005;21(4):495\u2013502.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"4747_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1586\/erp.11.5","volume":"11","author":"J Darb\u00e0","year":"2011","unstructured":"Darb\u00e0 J, et al. Epidemiology and societal costs of gastroesophageal reflux disease and Barrett\u2019s syndrome in Germany, Italy and Spain. Expert Rev Pharmacoecon Outcomes Res. 2011;11(2):225\u201332.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"6","key":"4747_CR9","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s41669-024-00521-7","volume":"8","author":"S Harper","year":"2024","unstructured":"Harper S, et al. The Economic Impact of Introducing RefluxStop for Refractory Gastroesophageal Reflux Disease on the Italian Healthcare System. PharmacoEconomics - Open. 2024;8(6):935\u201343.","journal-title":"PharmacoEconomics - Open"},{"key":"4747_CR10","doi-asserted-by":"publisher","unstructured":"Stawinski PM et al. Barrett\u2019s Esophagus: An Updated Review. Diagnostics (Basel). 2023;13(2):321. https:\/\/doi.org\/10.3390\/diagnostics13020321 Published 16 Jan 2023.","DOI":"10.3390\/diagnostics13020321"},{"issue":"1","key":"4747_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.36469\/jheor.2023.68191","volume":"10","author":"P Sharma","year":"2023","unstructured":"Sharma P, et al. Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett\u2019s Esophagus, and Barrett\u2019s Esophagus-Related Neoplasia in the United States. J Health Econ Outcomes Res. 2023;10(1):51\u20138.","journal-title":"J Health Econ Outcomes Res"},{"issue":"1","key":"4747_CR12","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1186\/s12913-024-11781-8","volume":"24","author":"P Maresova","year":"2024","unstructured":"Maresova P, et al. Diagnosis and treatment of patients with gastroesophageal reflux disease - a systematic review of cost-effectiveness and economic burden. BMC Health Serv Res. 2024;24(1):1351.","journal-title":"BMC Health Serv Res"},{"key":"4747_CR13","unstructured":"NICE. National Institute for Health and Care Excellence. Clinical guideline [CG184]: gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management. 2019."},{"issue":"2","key":"4747_CR14","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00464-022-09817-3","volume":"37","author":"BJ Slater","year":"2023","unstructured":"Slater BJ, et al. Multi-society consensus conference and guideline on the treatment of gastroesophageal reflux disease (GERD). Surg Endosc. 2023;37(2):781\u2013806.","journal-title":"Surg Endosc"},{"key":"4747_CR15","doi-asserted-by":"publisher","unstructured":"Katz PO et al. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Official J Am Coll Gastroenterol | ACG. 2022;117(1):27\u201356. https:\/\/doi.org\/10.14309\/ajg.0000000000001538.","DOI":"10.14309\/ajg.0000000000001538"},{"issue":"2","key":"4747_CR16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.gie.2024.10.008","volume":"101","author":"M Desai","year":"2025","unstructured":"Desai M, et al. American Society for Gastrointestinal Endoscopy guideline on the diagnosis and management of GERD: summary and recommendations. Gastrointest Endosc. 2025;101(2):267\u201384.","journal-title":"Gastrointest Endosc"},{"issue":"8","key":"4747_CR17","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.dld.2025.04.020","volume":"57","author":"EV Savarino","year":"2025","unstructured":"Savarino EV, et al. Italian guidelines for the diagnosis and management of gastro-esophageal reflux disease: Joint consensus from the Italian Societies of: Gastroenterology and Endoscopy (SIGE), Neurogastroenterology and Motility (SINGEM), Hospital Gastroenterologists and Endoscopists (AIGO), Digestive Endoscopy (SIED), and General Medicine (SIMG). Dig Liver Dis. 2025;57(8):1550\u201377.","journal-title":"Dig Liver Dis"},{"issue":"1","key":"4747_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12916-016-0718-z","volume":"14","author":"C Scarpignato","year":"2016","unstructured":"Scarpignato C, et al. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14(1):179.","journal-title":"BMC Med"},{"key":"4747_CR19","doi-asserted-by":"publisher","first-page":"765061","DOI":"10.3389\/fmed.2021.765061","volume":"8","author":"F Rettura","year":"2021","unstructured":"Rettura F, et al. Refractory Gastroesophageal Reflux Disease: A Management Update. Front Med (Lausanne). 2021;8:765061.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"4747_CR20","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s43856-024-00632-6","volume":"4","author":"J Labenz","year":"2024","unstructured":"Labenz J, Schoppmann SF. Improving treatment of people with gastro-esophageal reflux disease refractory to proton pump inhibitors. Commun Med (Lond). 2024;4(1):200.","journal-title":"Commun Med (Lond)"},{"issue":"35","key":"4747_CR21","doi-asserted-by":"publisher","first-page":"6500","DOI":"10.3748\/wjg.v23.i35.6500","volume":"23","author":"A Trifan","year":"2017","unstructured":"Trifan A, et al. Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis. World J Gastroenterol. 2017;23(35):6500\u201315.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"4747_CR22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.11005\/jbm.2018.25.3.141","volume":"25","author":"Y Nassar","year":"2018","unstructured":"Nassar Y, Richter S. Proton-pump Inhibitor Use and Fracture Risk: An Updated Systematic Review and Meta-analysis. J Bone Metab. 2018;25(3):141\u201351.","journal-title":"J Bone Metab"},{"issue":"5","key":"4747_CR23","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/intqhc\/mzaa041","volume":"32","author":"PA Nguyen","year":"2020","unstructured":"Nguyen PA, et al. Meta-analysis of proton pump inhibitors induced risk of community-acquired pneumonia. Int J Qual Health Care. 2020;32(5):292\u20139.","journal-title":"Int J Qual Health Care"},{"key":"4747_CR24","doi-asserted-by":"publisher","unstructured":"Poly TN et al. Proton Pump Inhibitor Use and Risk of Gastric Cancer: Current Evidence from Epidemiological Studies and Critical Appraisal. Cancers (Basel). 2022;14(13):3052. https:\/\/doi.org\/10.3390\/cancers14133052. Published 21 Jun 2022.","DOI":"10.3390\/cancers14133052"},{"issue":"2","key":"4747_CR25","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/ndt\/gfw470","volume":"33","author":"S Nochaiwong","year":"2018","unstructured":"Nochaiwong S, et al. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. Nephrol Dial Transpl. 2018;33(2):331\u201342.","journal-title":"Nephrol Dial Transpl"},{"issue":"8","key":"4747_CR26","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/apt.14955","volume":"48","author":"R Batchelor","year":"2018","unstructured":"Batchelor R, et al. Systematic review with meta-analysis: risk of adverse cardiovascular events with proton pump inhibitors independent of clopidogrel. Aliment Pharmacol Ther. 2018;48(8):780\u201396.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"4747_CR27","doi-asserted-by":"publisher","first-page":"e1332","DOI":"10.1016\/S2214-109X(19)30318-3","volume":"7","author":"WHO CVD","year":"2019","unstructured":"WHO CVD. Risk Chart Working Group. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob Health. 2019;7(10):e1332\u201345.","journal-title":"Lancet Glob Health"},{"issue":"4","key":"4747_CR28","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.hlc.2017.10.020","volume":"27","author":"TP Shiraev","year":"2018","unstructured":"Shiraev TP, Bullen A. Proton Pump Inhibitors and Cardiovascular Events: A Systematic Review. Heart Lung Circ. 2018;27(4):443\u201350.","journal-title":"Heart Lung Circ"},{"issue":"597","key":"4747_CR29","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.3399\/bjgp12X636065","volume":"62","author":"G Collins","year":"2012","unstructured":"Collins G, Altman D. Predicting the risk of chronic kidney disease in the UK: an evaluation of QKidney\u00ae scores using a primary care database. Br J Gen Pract. 2012;62(597):e243\u201350.","journal-title":"Br J Gen Pract"},{"issue":"1","key":"4747_CR30","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cegh.2017.12.008","volume":"7","author":"SS Hussain","year":"2019","unstructured":"Hussain SS, Habib A, Najmi A. Proton pump inhibitors use and risk of chronic kidney disease: Evidence-based meta-analysis of observational studies. Clin Epidemiol Global Health. 2019;7(1):46\u201352.","journal-title":"Clin Epidemiol Global Health"},{"issue":"4","key":"4747_CR31","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385\u201397.","journal-title":"Osteoporos Int"},{"issue":"1","key":"4747_CR32","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00198-015-3365-x","volume":"27","author":"B Zhou","year":"2016","unstructured":"Zhou B, et al. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int. 2016;27(1):339\u201347.","journal-title":"Osteoporos Int"},{"key":"4747_CR33","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1017\/S0950268819001559","volume":"147","author":"X Sun","year":"2019","unstructured":"Sun X, Douiri A, Gulliford M. Pneumonia incidence trends in UK primary care from 2002 to 2017: population-based cohort study. Epidemiol Infect. 2019;147:e263.","journal-title":"Epidemiol Infect"},{"issue":"6","key":"4747_CR34","doi-asserted-by":"publisher","first-page":"e0128004","DOI":"10.1371\/journal.pone.0128004","volume":"10","author":"AA Lambert","year":"2015","unstructured":"Lambert AA, et al. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS ONE. 2015;10(6):e0128004.","journal-title":"PLoS ONE"},{"key":"4747_CR35","unstructured":"Public Health England. Clostridium difficile infection: mandatory surveillance 2017\/18. 2018 5 May 2023]; Available from: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/724368\/CDI_summary_2018.pdf."},{"issue":"7","key":"4747_CR36","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/ajg.2012.179","volume":"107","author":"S Janarthanan","year":"2012","unstructured":"Janarthanan S, et al. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012;107(7):1001\u201310.","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"4747_CR37","doi-asserted-by":"publisher","first-page":"e017739","DOI":"10.1136\/bmjopen-2017-017739","volume":"7","author":"N Brusselaers","year":"2017","unstructured":"Brusselaers N, et al. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open. 2017;7(10):e017739.","journal-title":"BMJ Open"},{"key":"4747_CR38","doi-asserted-by":"publisher","unstructured":"ZehetnerJ, et al. Looking back on a gold standard: a systematic literature review of laparoscopic Nissen fundoplication as an anti-reflux treatment option. Eur Surg. 2024;56:143\u2013171. https:\/\/doi.org\/10.1007\/s10353-024-00836-z.","DOI":"10.1007\/s10353-024-00836-z"},{"key":"4747_CR39","doi-asserted-by":"publisher","unstructured":"Patel A, Gyawali C. The role of magnetic sphincter augmentation (MSA) in the gastroesophageal reflux disease (GERD) treatment pathway: the gastroenterology perspective. Dis Esophagus. 2023;36 Suppl 1:doad005. https:\/\/doi.org\/10.1093\/dote\/doad005.","DOI":"10.1093\/dote\/doad005"},{"issue":"1","key":"4747_CR40","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jamcollsurg.2015.02.025","volume":"221","author":"JL Reynolds","year":"2015","unstructured":"Reynolds JL, et al. Laparoscopic Magnetic Sphincter Augmentation vs Laparoscopic Nissen Fundoplication: A Matched-Pair Analysis of 100 Patients. J Am Coll Surg. 2015;221(1):123\u20138.","journal-title":"J Am Coll Surg"},{"issue":"3","key":"4747_CR41","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00464-014-3704-6","volume":"29","author":"EG Sheu","year":"2015","unstructured":"Sheu EG, et al. A comparative trial of laparoscopic magnetic sphincter augmentation and Nissen fundoplication. Surg Endosc. 2015;29(3):505\u20139.","journal-title":"Surg Endosc"},{"key":"4747_CR42","doi-asserted-by":"publisher","first-page":"111646","DOI":"10.1016\/j.ijscr.2025.111646","volume":"133","author":"P Ruiz-Cota","year":"2025","unstructured":"Ruiz-Cota P, et al. More than a mechanical problem: Dysphagia and new-onset ineffective esophageal motility after LINX(R) placement-a case report. Int J Surg Case Rep. 2025;133:111646.","journal-title":"Int J Surg Case Rep"},{"key":"4747_CR43","unstructured":"National Institute for. Health and Care Excellence. Interventional procedures guidance [IPG585]: Laparoscopic insertion of a magnetic titanium ring for gastro-oesophageal reflux disease. 2017 5 May 2023]; Available from: https:\/\/www.nice.org.uk\/guidance\/ipg585."},{"issue":"8","key":"4747_CR44","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1007\/s00464-016-5370-3","volume":"31","author":"D Skubleny","year":"2017","unstructured":"Skubleny D, et al. LINX(\u00ae) magnetic esophageal sphincter augmentation versus Nissen fundoplication for gastroesophageal reflux disease: a systematic review and meta-analysis. Surg Endosc. 2017;31(8):3078\u201384.","journal-title":"Surg Endosc"},{"issue":"8","key":"4747_CR45","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1007\/s11605-018-3775-0","volume":"22","author":"ET Alicuben","year":"2018","unstructured":"Alicuben ET, et al. Worldwide Experience with Erosion of the Magnetic Sphincter Augmentation Device. J Gastrointest Surg. 2018;22(8):1442\u20137.","journal-title":"J Gastrointest Surg"},{"key":"4747_CR46","unstructured":"FDA Summary of Safety and Effectiveness Data (SSED) \u2013 LINX\u00ae Reflux Management System. Premarket Approval (PMA) P100049. 2012, U.S. Food and Drug Administration. Applicant: Torax Medical, Inc., 4188 Lexington Avenue North, Shoreview, MN 55126. Panel recommendation: January 11, 2012. FDA approval: March 22, 2012.: Silver Spring, MD."},{"issue":"1","key":"4747_CR47","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11605-019-04331-9","volume":"24","author":"S Ayazi","year":"2020","unstructured":"Ayazi S, et al. Magnetic Sphincter Augmentation and Postoperative Dysphagia: Characterization, Clinical Risk Factors, and Management. J Gastrointest Surg. 2020;24(1):39\u201349.","journal-title":"J Gastrointest Surg"},{"issue":"4","key":"4747_CR48","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/SLE.0000000000000785","volume":"30","author":"C Tsai","year":"2020","unstructured":"Tsai C, et al. Postoperative Dysphagia Following Magnetic Sphincter Augmentation for Gastroesophageal Reflux Disease. Surg Laparosc Endosc Percutan Tech. 2020;30(4):322\u20136.","journal-title":"Surg Laparosc Endosc Percutan Tech"},{"issue":"8","key":"4747_CR49","doi-asserted-by":"publisher","first-page":"4956","DOI":"10.1007\/s00464-025-11842-x","volume":"39","author":"SJ Bloomsburg","year":"2025","unstructured":"Bloomsburg SJ, Duncan AJ, Chen S. The failure pattern for the magnetic sphincter augmentation device: a single-institution case series with literature review. Surg Endosc. 2025;39(8):4956\u201364.","journal-title":"Surg Endosc"},{"issue":"8","key":"4747_CR50","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1007\/s00464-015-4635-6","volume":"30","author":"JL Reynolds","year":"2016","unstructured":"Reynolds JL, et al. Charges, outcomes, and complications: a comparison of magnetic sphincter augmentation versus laparoscopic Nissen fundoplication for the treatment of GERD. Surg Endosc. 2016;30(8):3225\u201330.","journal-title":"Surg Endosc"},{"issue":"5","key":"4747_CR51","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1007\/s00464-019-07021-4","volume":"34","author":"S Ayazi","year":"2020","unstructured":"Ayazi S, et al. Comparison of surgical payer costs and implication on the healthcare expenses between laparoscopic magnetic sphincter augmentation (MSA) and laparoscopic Nissen fundoplication (LNF) in a large healthcare system. Surg Endosc. 2020;34(5):2279\u201386.","journal-title":"Surg Endosc"},{"issue":"4","key":"4747_CR52","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/S1542-3565(03)00138-1","volume":"1","author":"CA Dire","year":"2003","unstructured":"Dire CA, et al. The economics of laparoscopic Nissen fundoplication. Clin Gastroenterol Hepatol. 2003;1(4):328\u201332.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"4747_CR53","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jamcollsurg.2017.03.019","volume":"225","author":"F Banki","year":"2017","unstructured":"Banki F, et al. Laparoscopic Reoperative Antireflux Surgery Is More Cost-Effective than Open Approach. J Am Coll Surg. 2017;225(2):235\u201342.","journal-title":"J Am Coll Surg"},{"issue":"1","key":"4747_CR54","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12893-020-00794-9","volume":"20","author":"M Bjelovi\u0107","year":"2020","unstructured":"Bjelovi\u0107 M, et al. Non-active implantable device treating acid reflux with a new dynamic treatment approach: 1-year results. BMC Surg. 2020;20(1):159.","journal-title":"BMC Surg"},{"issue":"9","key":"4747_CR55","doi-asserted-by":"publisher","first-page":"6163","DOI":"10.1007\/s00464-025-11979-9","volume":"39","author":"L H\u00e1rsanyi","year":"2025","unstructured":"H\u00e1rsanyi L, et al. Five-year clinical outcomes of RefluxStop surgery in the treatment of acid reflux: a prospective multicenter trial of safety and effectiveness. Surg Endosc. 2025;39(9):6163\u201379.","journal-title":"Surg Endosc"},{"issue":"2","key":"4747_CR56","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s10620-024-08788-w","volume":"70","author":"L Hars\u00e1nyi","year":"2024","unstructured":"Hars\u00e1nyi L, Kincses Z, Altorjay \u00c1. Acid Reflux Management with the RefluxStop Implant: A Prospective Multicenter Trial with 3-Year Outcomes. Dig Dis Sci. 2024;70(2):665\u201374.","journal-title":"Dig Dis Sci"},{"issue":"10","key":"4747_CR57","doi-asserted-by":"publisher","first-page":"6060","DOI":"10.1007\/s00464-024-11114-0","volume":"38","author":"L Hars\u00e1nyi","year":"2024","unstructured":"Hars\u00e1nyi L, et al. Treating acid reflux without compressing the food passageway: 4-year safety and clinical outcomes with the RefluxStop device in a prospective multicenter study. Surg Endosc. 2024;38(10):6060\u20139.","journal-title":"Surg Endosc"},{"issue":"7","key":"4747_CR58","doi-asserted-by":"publisher","first-page":"4615","DOI":"10.1007\/s00464-025-11818-x","volume":"39","author":"LK Hars\u00e1nyi","year":"2025","unstructured":"Hars\u00e1nyi LK, Veselinovi\u0107 Z, Zehetner M, Altorjay J. Food passageway-related sequelae in the RefluxStop prospective multicenter trial: Patient-centric outcomes of dysphagia, odynophagia, gas-bloating, and inability to belch and\/or vomit at 5 years. Surg Endosc. 2025;39(7):4615\u201327.","journal-title":"Surg Endosc"},{"key":"4747_CR59","doi-asserted-by":"publisher","unstructured":"Schoppmann S et al. Safety Results of 602 Patients With GERD Treated by RefluxStop Surgery: A Multi-Center Real-World Observational Study by the RefluxStop Evaluation Group With Mean Follow-Up of 2 Years. Abstract ID: 128. Presented at the American Foregut Society (AFS) 2025. Foregut. 2025;0(0). https:\/\/doi.org\/10.1177\/26345161251371922. 2025.","DOI":"10.1177\/26345161251371922"},{"issue":"1","key":"4747_CR60","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40258-012-0006-9","volume":"11","author":"A Kirisits","year":"2013","unstructured":"Kirisits A, Redekop WK. The Economic Evaluation of Medical Devices. Appl Health Econ Health Policy. 2013;11(1):15\u201326.","journal-title":"Appl Health Econ Health Policy"},{"issue":"6","key":"4747_CR61","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s40273-023-01265-8","volume":"41","author":"B Wouterse","year":"2023","unstructured":"Wouterse B, et al. The Value of Health in a Cost-Effectiveness Analysis: Theory Versus Practice. PharmacoEconomics. 2023;41(6):607\u201317.","journal-title":"PharmacoEconomics"},{"key":"4747_CR62","volume-title":"Health system efficiency: How to make measurement matter for policy and management","author":"R Thomas","year":"2016","unstructured":"Thomas R, Chalkidou K. Cost\u2013effectiveness analysis. Health system efficiency: How to make measurement matter for policy and management. European Observatory on Health Systems and Policies: Copenhagen (Denmark); 2016. J. Cylus, I. Papanicolas, and P.C. Smith, Editors."},{"issue":"7","key":"4747_CR63","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s40273-018-0672-z","volume":"36","author":"AE Attema","year":"2018","unstructured":"Attema AE, Brouwer WBF, Claxton K. Discounting in Economic Evaluations. PharmacoEconomics. 2018;36(7):745\u201358.","journal-title":"PharmacoEconomics"},{"issue":"1","key":"4747_CR64","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/009286150103500122","volume":"35","author":"S Capri","year":"2001","unstructured":"Capri S, et al. Guidelines for Economic Evaluations in Italy: Recommendations from The Italian Group of Pharmacoeconomic Studies. Drug Inform journal: DIJ \/ Drug Inform Association. 2001;35(1):189\u2013201.","journal-title":"Drug Inform journal: DIJ \/ Drug Inform Association"},{"issue":"1","key":"4747_CR65","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1080\/13696998.2023.2201063","volume":"26","author":"S Harper","year":"2023","unstructured":"Harper S, et al. Cost-effectiveness of a novel, non-active implantable device as a treatment for refractory gastro-esophageal reflux disease. J Med Econ. 2023;26(1):603\u201313.","journal-title":"J Med Econ"},{"issue":"1","key":"4747_CR66","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1080\/13696998.2024.2362564","volume":"27","author":"S Harper","year":"2024","unstructured":"Harper S, et al. Cost-effectiveness of the RefluxStop device for management of refractory gastroesophageal reflux disease in Switzerland. J Med Econ. 2024;27(1):805\u201315.","journal-title":"J Med Econ"},{"issue":"1","key":"4747_CR67","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12962-025-00665-1","volume":"23","author":"S Harper","year":"2025","unstructured":"Harper S, et al. Cost-effectiveness of RefluxStop compared to proton pump inhibitors and Nissen fundoplication for management of persistent gastroesophageal reflux disease in Norway. Cost Eff Resour Alloc. 2025;23(1):63.","journal-title":"Cost Eff Resour Alloc"},{"key":"4747_CR68","doi-asserted-by":"crossref","unstructured":"Harper S et al. A cost-effectiveness analysis of RefluxStop against relevant therapeutic alternatives for chronic gastroesophageal reflux disease in Sweden. Expert Rev Pharmacoecon Outcomes Res. 2025;25(3):353\u2013365.","DOI":"10.1080\/14737167.2024.2417774"},{"issue":"31","key":"4747_CR69","doi-asserted-by":"publisher","first-page":"p1","DOI":"10.3310\/hta12310","volume":"12","author":"A Grant","year":"2008","unstructured":"Grant A, et al. The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease - a UK collaborative study. The REFLUX trial. Health Technol Assess. 2008;12(31):p1\u2013181.","journal-title":"Health Technol Assess"},{"issue":"16","key":"4747_CR70","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1811424","volume":"381","author":"SJ Spechler","year":"2019","unstructured":"Spechler SJ, et al. Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn. N Engl J Med. 2019;381(16):1513\u201323.","journal-title":"N Engl J Med"},{"issue":"10","key":"4747_CR71","doi-asserted-by":"publisher","first-page":"829","DOI":"10.2165\/00019053-200725100-00003","volume":"25","author":"L Bojke","year":"2007","unstructured":"Bojke L, Hornby E, Sculpher M. A comparison of the cost effectiveness of pharmacotherapy or surgery (laparoscopic fundoplication) in the treatment of GORD. PharmacoEconomics. 2007;25(10):829\u201341.","journal-title":"PharmacoEconomics"},{"key":"4747_CR72","unstructured":"National Institute for Health and Care Excellence (NICE). Dyspepsia and gastro-oesophageal reflux disease. Appendix H: Full Health Economics Report;. 2014 5 May 2023]; Available from: https:\/\/www.nice.org.uk\/guidance\/cg184\/evidence\/appendix-h-full-health-economics-report-pdf-6955335252."},{"key":"4747_CR73","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-007-7596-1","volume-title":"Self-Reported Population Health: An International Perspective based on EQ-5D","author":"A Szende","year":"2014","unstructured":"Szende A, et al. Self-Reported Population Health: An International Perspective based on EQ-5D. 1 ed. Dordrecht (NL): Springer; 2014.","edition":"1"},{"issue":"5","key":"4747_CR74","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1007\/s00464-002-8568-5","volume":"17","author":"WG Ainslie","year":"2003","unstructured":"Ainslie WG, et al. Micropuncture cholecystectomy vs conventional laparoscopic cholecystectomy: a randomized controlled trial. Surg Endosc. 2003;17(5):766\u201372.","journal-title":"Surg Endosc"},{"issue":"5","key":"4747_CR75","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/clpt.2013.13","volume":"93","author":"JC Bouvy","year":"2013","unstructured":"Bouvy JC, et al. The cost-effectiveness of periodic safety update reports for biologicals in Europe. Clin Pharmacol Ther. 2013;93(5):433\u201342.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"4747_CR76","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1080\/03007995.2018.1552407","volume":"35","author":"V Pollit","year":"2019","unstructured":"Pollit V, et al. A cost-effectiveness analysis of endoscopic eradication therapy for management of dysplasia arising in patients with Barrett\u2019s oesophagus in the United Kingdom. Curr Med Res Opin. 2019;35(5):805\u201315.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"4747_CR77","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/aje\/kwn121","volume":"168","author":"F Yousef","year":"2008","unstructured":"Yousef F, et al. The incidence of esophageal cancer and high-grade dysplasia in Barrett\u2019s esophagus: a systematic review and meta-analysis. Am J Epidemiol. 2008;168(3):237\u201349.","journal-title":"Am J Epidemiol"},{"key":"4747_CR78","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/1471-2407-13-329","volume":"13","author":"S Francisci","year":"2013","unstructured":"Francisci S, et al. Cost profiles of colorectal cancer patients in Italy based on individual patterns of care. BMC Cancer. 2013;13:329.","journal-title":"BMC Cancer"},{"issue":"Suppl 3","key":"4747_CR79","doi-asserted-by":"publisher","first-page":"iii73","DOI":"10.1093\/ndt\/gfs269","volume":"27","author":"M Kerr","year":"2012","unstructured":"Kerr M, et al. Estimating the financial cost of chronic kidney disease to the NHS in England. Nephrol Dial Transpl. 2012;27(Suppl 3):iii73\u201380.","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"4747_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.diagmicrobio.2007.07.002","volume":"60","author":"E Carretto","year":"2008","unstructured":"Carretto E, et al. Use of the DiversiLab semiautomated repetitive-sequence-based polymerase chain reaction for epidemiologic analysis on Acinetobacter baumannii isolates in different Italian hospitals. Diagn Microbiol Infect Dis. 2008;60(1):1\u20137.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"4747_CR81","first-page":"680737","volume":"2014","author":"DP Roggeri","year":"2014","unstructured":"Roggeri DP, Roggeri A, Salomone M. Chronic Kidney Disease: Evolution of Healthcare Costs and Resource Consumption from Predialysis to Dialysis in Piedmont Region, Italy. Adv Nephrol. 2014;2014(1):680737.","journal-title":"Adv Nephrol"},{"issue":"7","key":"4747_CR82","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.amjmed.2019.01.003","volume":"132","author":"D Pastori","year":"2019","unstructured":"Pastori D, et al. ABC (Atrial fibrillation Better Care) Pathway and Healthcare Costs in Atrial Fibrillation: The ATHERO-AF Study. Am J Med. 2019;132(7):856\u201361.","journal-title":"Am J Med"},{"issue":"1","key":"4747_CR83","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s11657-013-0137-0","volume":"8","author":"A Svedbom","year":"2013","unstructured":"Svedbom A, et al. Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos. 2013;8(1):137.","journal-title":"Arch Osteoporos"},{"issue":"1","key":"4747_CR84","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1080\/13696998.2021.1917139","volume":"24","author":"MA Chaudhary","year":"2021","unstructured":"Chaudhary MA, et al. Cost-effectiveness of nivolumab in squamous and non-squamous non-small cell lung cancer in Canada and Sweden: an update with 5-year data. J Med Econ. 2021;24(1):607\u201319.","journal-title":"J Med Econ"},{"issue":"7","key":"4747_CR85","doi-asserted-by":"publisher","first-page":"3208","DOI":"10.1007\/s00464-018-6038-y","volume":"32","author":"TR Palser","year":"2018","unstructured":"Palser TR, et al. Variation in laparoscopic anti-reflux surgery across England: a 5-year review. Surg Endosc. 2018;32(7):3208\u201314.","journal-title":"Surg Endosc"},{"key":"4747_CR86","unstructured":"National Institute for Health and Care Excellence. Quality standard [QS110]: Pneumonia in adults. 2016 5 May 2023]; Available from: https:\/\/www.nice.org.uk\/guidance\/qs110."},{"issue":"11","key":"4747_CR87","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.jval.2019.06.011","volume":"22","author":"T Shiri","year":"2019","unstructured":"Shiri T, et al. Pneumococcal Disease: A Systematic Review of Health Utilities, Resource Use, Costs, and Economic Evaluations of Interventions. Value Health. 2019;22(11):1329\u201344.","journal-title":"Value Health"},{"key":"4747_CR88","unstructured":"National Institute for Health and Care Excellence (NICE). Technology appraisal guidance [TA378]: ramucirumab for treating advanced gastric cancer or gastro\u2013oesophageal junction adenocarcinoma previously treated with chemotherapy. 2016."},{"key":"4747_CR89","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1332\/174426410X482999","volume":"6","author":"I Shemilt","year":"2010","unstructured":"Shemilt I, Thomas J, Morciano M. A web-based tool for adjusting costs to a specific target currency and price year. Evid Policy J Res Debate Pract. 2010;6:51\u201360.","journal-title":"Evid Policy J Res Debate Pract"},{"issue":"11","key":"4747_CR90","doi-asserted-by":"publisher","first-page":"e012977","DOI":"10.1136\/bmjopen-2016-012977","volume":"6","author":"M Laudicella","year":"2016","unstructured":"Laudicella M, et al. Impact of laparoscopic versus open surgery on hospital costs for colon cancer: a population-based retrospective cohort study. BMJ Open. 2016;6(11):e012977.","journal-title":"BMJ Open"},{"key":"4747_CR91","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ijid.2015.05.013","volume":"36","author":"A Asensio","year":"2015","unstructured":"Asensio A, et al. The impact of Clostridium difficile infection on resource use and costs in hospitals in Spain and Italy: a matched cohort study. Int J Infect Dis. 2015;36:31\u20138.","journal-title":"Int J Infect Dis"},{"issue":"6","key":"4747_CR92","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40273-021-01112-8","volume":"40","author":"D Husereau","year":"2022","unstructured":"Husereau D, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. PharmacoEconomics. 2022;40(6):601\u20139.","journal-title":"PharmacoEconomics"},{"issue":"5","key":"4747_CR93","first-page":"e24695","volume":"14","author":"A Messori","year":"2022","unstructured":"Messori A, Trippoli S. Estimation of Value-Based Price for Five High-Technology Medical Devices Approved by a Regional Health Technology Assessment Committee in Italy. Cureus. 2022;14(5):e24695.","journal-title":"Cureus"},{"key":"4747_CR94","doi-asserted-by":"crossref","unstructured":"Di Minno G, Ravasio R. Cost-effectiveness analysis of caplacizumab in the new standard of care for immune Thrombotic Thrombocytopenic Purpura in Italy. Volume 8. Global & Regional Health Technology Assessment; 2021. pp. 43\u201352.","DOI":"10.33393\/grhta.2021.2191"},{"issue":"3","key":"4747_CR95","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1159\/000475842","volume":"10","author":"M Lucchese","year":"2017","unstructured":"Lucchese M, et al. Cost-Utility Analysis of Bariatric Surgery in Italy: Results of Decision-Analytic Modelling. Obes Facts. 2017;10(3):261\u201372.","journal-title":"Obes Facts"},{"issue":"25","key":"4747_CR96","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1016\/j.jacc.2008.09.018","volume":"52","author":"DJ Cohen","year":"2008","unstructured":"Cohen DJ, Reynolds MR. Interpreting the results of cost-effectiveness studies. J Am Coll Cardiol. 2008;52(25):2119\u201326.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"4747_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.36469\/jheor.2024.90924","volume":"11","author":"S Harper","year":"2024","unstructured":"Harper S, et al. Budget Impact of RefluxStop\u2122 as a Treatment for Patients with Refractory Gastro-oesophageal Reflux Disease in the United Kingdom. J Health Econ Outcomes Res. 2024;11(1):1\u20137.","journal-title":"J Health Econ Outcomes Res"},{"key":"4747_CR98","doi-asserted-by":"crossref","unstructured":"Harper S, et al. Cost-Effectiveness of RefluxStop Versus Nissen Fundoplication and Proton Pump Inhibitors for Refractory Gastroesophageal Reflux Disease: A Spanish Healthcare Perspective. Pharmacoecon Open; 2026.","DOI":"10.1007\/s41669-025-00636-5"},{"key":"4747_CR99","unstructured":"OECD. Health at a Glance 2021: OECD Indicators. Paris; 2021."},{"key":"4747_CR100","first-page":"5","volume":"14","author":"F Fiorentino","year":"2021","unstructured":"Fiorentino F, Urbinati D. First Italian guidelines for the economic evaluation of health technologies: how do they compare to NICE standards? GIHTAD. 2021;14:5.","journal-title":"GIHTAD"},{"key":"4747_CR101","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.sopen.2024.12.003","volume":"23","author":"T Lehmann","year":"2025","unstructured":"Lehmann T, \u0160imkus M, Oehler C. A retrospective study assessing RefluxStop surgery for gastroesophageal reflux disease: Clinical outcomes in 79 patients from Germany. Surg Open Sci. 2025;23:9\u201315.","journal-title":"Surg Open Sci"},{"issue":"5","key":"4747_CR102","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1089\/lap.2024.0390","volume":"35","author":"M Elshafei","year":"2025","unstructured":"Elshafei M. Experience With an Innovative Surgical Treatment Option for Gastroesophageal Reflux Disease: Results of 28 Patients in a Retrospective Analysis. J Laparoendosc Adv Surg Tech A. 2025;35(5):357\u201364.","journal-title":"J Laparoendosc Adv Surg Tech A"},{"issue":"1","key":"4747_CR103","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s10029-025-03339-2","volume":"29","author":"Y Borb\u00e9ly","year":"2025","unstructured":"Borb\u00e9ly Y, et al. A safety and effectiveness evaluation of refluxstop in the treatment of acid reflux comparing large and small hiatal hernia groups: results from 99 patients in Switzerland with up to 4-years follow-up. Hernia. 2025;29(1):156.","journal-title":"Hernia"},{"issue":"1","key":"4747_CR104","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s00423-024-03264-5","volume":"409","author":"Y Fringeli","year":"2024","unstructured":"Fringeli Y, et al. Short-term results of laparoscopic anti-reflux surgery with the RefluxStop device in patients with gastro-esophageal reflux disease and ineffective esophageal motility. Langenbecks Arch Surg. 2024;409(1):78.","journal-title":"Langenbecks Arch Surg"},{"issue":"2","key":"4747_CR105","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jval.2010.09.004","volume":"14","author":"R Goeree","year":"2011","unstructured":"Goeree R, et al. Cost-utility of laparoscopic Nissen fundoplication versus proton pump inhibitors for chronic and controlled gastroesophageal reflux disease: a 3-year prospective randomized controlled trial and economic evaluation. Value Health. 2011;14(2):263\u201373.","journal-title":"Value Health"},{"key":"4747_CR106","doi-asserted-by":"publisher","unstructured":"Tabaeian SP et al. Economic evaluation of proton pump inhibitors in patients with gastro-oesophageal reflux disease: a systematic review. BMJ Open Gastroenterol. 2024;11(1):e001465. https:\/\/doi.org\/10.1136\/bmjgast-2024-001465. Published 20 Dec 2024.","DOI":"10.1136\/bmjgast-2024-001465"},{"issue":"2","key":"4747_CR107","doi-asserted-by":"publisher","first-page":"215","DOI":"10.5056\/jnm19188","volume":"26","author":"S Park","year":"2020","unstructured":"Park S, et al. Anti-reflux Surgery Versus Proton Pump Inhibitors for Severe Gastroesophageal Reflux Disease: A Cost-Effectiveness Study in Korea. J Neurogastroenterol Motil. 2020;26(2):215\u201323.","journal-title":"J Neurogastroenterol Motil"},{"issue":"6","key":"4747_CR108","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/bjs.4933","volume":"92","author":"R Cookson","year":"2005","unstructured":"Cookson R, et al. Short-term cost effectiveness and long-term cost analysis comparing laparoscopic Nissen fundoplication with proton-pump inhibitor maintenance for gastro-oesophageal reflux disease. Br J Surg. 2005;92(6):700\u20136.","journal-title":"Br J Surg"},{"issue":"1","key":"4747_CR109","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.surg.2014.05.027","volume":"157","author":"LM Funk","year":"2015","unstructured":"Funk LM, et al. Long-term cost-effectiveness of medical, endoscopic and surgical management of gastroesophageal reflux disease. Surgery. 2015;157(1):126\u201336.","journal-title":"Surgery"},{"key":"4747_CR110","doi-asserted-by":"publisher","first-page":"b2576","DOI":"10.1136\/bmj.b2576","volume":"339","author":"D Epstein","year":"2009","unstructured":"Epstein D, Bojke L, Sculpher MJ. Laparoscopic fundoplication compared with medical management for gastro-oesophageal reflux disease: cost effectiveness study. BMJ. 2009;339:b2576.","journal-title":"BMJ"},{"issue":"7351","key":"4747_CR111","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1136\/bmj.324.7351.1448","volume":"324","author":"P McCulloch","year":"2002","unstructured":"McCulloch P, et al. Randomised trials in surgery: problems and possible solutions. BMJ. 2002;324(7351):1448\u201351.","journal-title":"BMJ"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04747-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04747-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04747-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:01:50Z","timestamp":1777629710000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04747-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":111,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4747"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04747-z","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors reviewed and approved the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SH and SM work for a consultancy company that was commissioned by Implantica to develop the original cost-effectiveness model [\n                      \n                      ]. MK is an employee of Implantica A.G. Other authors have no personal conflicts to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"266"}}